{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:30:13Z","timestamp":1786487413759,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.108243","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:35:56Z","timestamp":1783427756000},"page":"108243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America"],"prefix":"10.1016","volume":"11","author":[{"given":"L.","family":"Hart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":false,"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8592-2239","authenticated-orcid":false,"given":"P.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6272-8844","authenticated-orcid":false,"given":"V.K.","family":"Gadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mavros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5231-1260","authenticated-orcid":false,"given":"M.","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0408-4835","authenticated-orcid":false,"given":"N.","family":"Boualam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108243_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108243_bib3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2\u2212 advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108243_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108243_bib5","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108243_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108243_bib10","series-title":"East Hanover","year":"2024"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108243_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.34085","article-title":"The validity of progression-free survival 2 as a surrogate trial end point for overall survival","volume":"128","author":"Woodford","year":"2022","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108243_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.34748","article-title":"Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database","volume":"154","author":"Rugo","year":"2024","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108243_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100332","article-title":"Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2\u2212 metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials","volume":"6","author":"Munzone","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108243_bib15","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fonc.2020.01349","article-title":"Systematic review and meta-analysis of correlation of progression-free survival-2 and overall survival in solid tumors","volume":"10","author":"Chowdhury","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108243_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108243_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2\u2212 advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108243_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108243_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.108243_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115225","article-title":"Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+\/HER2\u2212 advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials","volume":"217","author":"Hart","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108243_bib22","article-title":"UK multicentre real-world data of the use of cyclin-dependent kinase 4\/6 inhibitors in metastatic breast cancer","volume":"5","author":"Gullick","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108243_bib23","doi-asserted-by":"crossref","first-page":"8488","DOI":"10.3390\/ijms24108488","article-title":"Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","volume":"24","author":"Cejuela","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108243_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s44276-024-00070-w","article-title":"Real-world effectiveness of CDK 4\/6 inhibitors in estrogen-positive metastatic breast cancer","volume":"2","author":"Gehrchen","year":"2024","journal-title":"BJC Rep"},{"issue":"21","key":"10.1016\/j.esmoop.2026.108243_bib25","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.3390\/cancers15215164","article-title":"Clinical impact of CDK4\/6 inhibitors in de novo or PR- or very elderly post-menopausal ER+\/HER2\u2212 advanced breast cancers","volume":"15","author":"Tang","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108243_bib26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/ijc.35296","article-title":"Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive\/HER2-negative metastatic breast cancer with real-world data from the OPAL registry","volume":"156","author":"Thill","year":"2025","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108243_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104103","article-title":"Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2\u2212 metastatic breast cancer in the US real-world setting","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108243_bib28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108243_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40487-025-00394-8","article-title":"Investigating real-world evidence and reported survival outcomes of CDK4\/6 inhibitors in HR+\/HER2\u2212 advanced breast cancer","volume":"14","author":"Sammons","year":"2026","journal-title":"Oncol Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602185X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292602185X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:53:38Z","timestamp":1786485218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292602185X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S205970292602185X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108243","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108243"}}